M Nørgaard1, K Veres2, E M Didden3, D Wormser3, M Magyari4. 1. Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital, 8200 Aarhus N, Denmark. Electronic address: mn@clin.au.dk. 2. Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital, 8200 Aarhus N, Denmark. 3. Hoffman-La Roche Ltd, Basel, Switzerland. 4. The Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Denmark; The Danish Multiple Sclerosis Registry, Department of Neurology, Rigshospitalet, Denmark.
Abstract
BACKGROUND: Introduction of disease modifying treatment may have increased the cancer incidence in multiple sclerosis patients. Our aim was to estimate the incidence of any cancer, malignant melanoma, nonmelanoma skin cancer, and female breast cancer, and cancer specific mortality in multiple sclerosis patients diagnosed in 1995-2015 i.e. after introduction of disease modifying treatment. METHODS: Linking various Danish medical registers, we compared observed cancer incidence and cancer-specific mortality in multiple sclerosis patients versus expected based on general population rates. RESULTS: Among 10,752 multiple sclerosis patients, we identified 5.76 incident cancers per 1,000 person-years. The standardized incidence ratio was 0.98 (95% confidence interval [CI], 0.90-1.06) for any cancer, 0.99 (95% CI, 0.84-1.15) for non-melanoma skin cancer, and 0.98 (95% CI, 0.81-1.18) for female breast cancer. For malignant melanoma, the standardized incidence ratio was 1.51 (95% CI, 1.13-1.98) for the entire period (1995-2015) but 1.16 (95% CI, 0.62-1.99) for 2005-2015. The overall mortality rate was 1.31 (95% CI, 1.09-1.53) per 1000 person-years with a standardized mortality ratio of 0.99 (95% CI, 0.83-1.17). CONCLUSION: In this nationwide study, multiple sclerosis patients did not have increased cancer incidence or increased cancer-specific mortality. We observed an increased risk of malignant melanoma mainly attributed to increased risk in the first part of our study period.
BACKGROUND: Introduction of disease modifying treatment may have increased the cancer incidence in multiple sclerosispatients. Our aim was to estimate the incidence of any cancer, malignant melanoma, nonmelanoma skin cancer, and female breast cancer, and cancer specific mortality in multiple sclerosispatients diagnosed in 1995-2015 i.e. after introduction of disease modifying treatment. METHODS: Linking various Danish medical registers, we compared observed cancer incidence and cancer-specific mortality in multiple sclerosispatients versus expected based on general population rates. RESULTS: Among 10,752 multiple sclerosispatients, we identified 5.76 incident cancers per 1,000 person-years. The standardized incidence ratio was 0.98 (95% confidence interval [CI], 0.90-1.06) for any cancer, 0.99 (95% CI, 0.84-1.15) for non-melanoma skin cancer, and 0.98 (95% CI, 0.81-1.18) for female breast cancer. For malignant melanoma, the standardized incidence ratio was 1.51 (95% CI, 1.13-1.98) for the entire period (1995-2015) but 1.16 (95% CI, 0.62-1.99) for 2005-2015. The overall mortality rate was 1.31 (95% CI, 1.09-1.53) per 1000 person-years with a standardized mortality ratio of 0.99 (95% CI, 0.83-1.17). CONCLUSION: In this nationwide study, multiple sclerosispatients did not have increased cancer incidence or increased cancer-specific mortality. We observed an increased risk of malignant melanoma mainly attributed to increased risk in the first part of our study period.
Authors: Martin S Weber; Mathias Buttmann; Sven G Meuth; Petra Dirks; Erwan Muros-Le Rouzic; Julius C Eggebrecht; Stefanie Hieke-Schulz; Jost Leemhuis; Tjalf Ziemssen Journal: Front Neurol Date: 2022-05-09 Impact factor: 4.086
Authors: Dimitrios Papadopoulos; Panagiotis Gklinos; Giorgos Psarros; Konstantina Drellia; Eumorphia Maria Delicha; Tim Friede; Dimos D Mitsikostas; Richard S Nicholas Journal: J Neurol Date: 2022-01-23 Impact factor: 4.849
Authors: Mette Nørgaard; Katalin Veres; Finn T Sellebjerg; Lise S Svingel; Caroline Foch; Emmanuelle Boutmy; Meritxell Sabidó; Melinda Magyari Journal: Mult Scler J Exp Transl Clin Date: 2021-11-23
Authors: Maria Luigia Carbone; Pedro Miguel Lacal; Serena Messinese; Laura De Giglio; Carlo Pozzilli; Severino Persechino; Cinzia Mazzanti; Cristina Maria Failla; Gianluca Pagnanelli Journal: Int J Mol Sci Date: 2020-04-22 Impact factor: 5.923
Authors: Stephen L Hauser; Ludwig Kappos; Douglas L Arnold; Amit Bar-Or; Bruno Brochet; Robert T Naismith; Anthony Traboulsee; Jerry S Wolinsky; Shibeshih Belachew; Harold Koendgen; Victoria Levesque; Marianna Manfrini; Fabian Model; Stanislas Hubeaux; Lahar Mehta; Xavier Montalban Journal: Neurology Date: 2020-07-20 Impact factor: 9.910
Authors: Stephen L Hauser; Ludwig Kappos; Xavier Montalban; Licinio Craveiro; Cathy Chognot; Richard Hughes; Harold Koendgen; Noemi Pasquarelli; Ashish Pradhan; Kalpesh Prajapati; Jerry S Wolinsky Journal: Neurology Date: 2021-09-02 Impact factor: 9.910